← Back to Search

99mTc-PYP Scan for Aortic Stenosis

Phase < 1
Recruiting
Led By Omar F Abou Ezzeddine, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 75 years
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Study Summary

This trial is testing a new way to detect a heart condition called transthyretin cardiac amyloidosis (TTR-CA) in people with aortic stenosis.

Who is the study for?
This trial is for people aged 75 or older living in Southeast Minnesota with moderate to severe aortic stenosis, which means their heart's aortic valve opening is smaller than normal. They can't have had recent heart surgery, major chest trauma, or a heart attack within the last month and should not have taken the drug Plaquenil.Check my eligibility
What is being tested?
The study aims to find out how common transthyretin cardiac amyloidosis (a type of heart disease where abnormal proteins build up) is among those with narrowed heart valves. It uses a special imaging test called 99mTc-PYP SPECT/CT to detect this condition.See study design
What are the potential side effects?
While specific side effects are not listed for this diagnostic procedure, generally such scans may cause discomfort at injection site, allergic reactions to the tracer substance used, and exposure to low levels of radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 75 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Prevalence of TTR-CA in patients with moderate and severe aortic stenosis

Trial Design

1Treatment groups
Experimental Treatment
Group I: SPECT/CTExperimental Treatment1 Intervention
99mTc-PYP single-photon positive emission computed tomography with computed tomography
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
99mTc-PYP
2017
Completed Early Phase 1
~290

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,212 Previous Clinical Trials
3,766,838 Total Patients Enrolled
Omar F Abou Ezzeddine, MDPrincipal InvestigatorMayo Clinic

Media Library

SPECT/CT Clinical Trial Eligibility Overview. Trial Name: NCT04899180 — Phase < 1
Transthyretin Amyloid Cardiomyopathy Research Study Groups: SPECT/CT
Transthyretin Amyloid Cardiomyopathy Clinical Trial 2023: SPECT/CT Highlights & Side Effects. Trial Name: NCT04899180 — Phase < 1
SPECT/CT 2023 Treatment Timeline for Medical Study. Trial Name: NCT04899180 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the participant count for this medical study?

"Affirmative. According to the information hosted on clinicaltrials.gov, this research endeavour is actively recruiting patients and was initially announced on November 1st 2022 with an edit made 10 days later. The study requires a total of 200 participants from just one medical facility."

Answered by AI

Are any individuals being sought out to participate in this experiment?

"Yes, indeed. According to clinicaltrials.gov, this research study was first published on November 1st 2022 and the information was recently updated on the 10th of that month. The investigators need 200 participants across one medical centre for the trial's completion."

Answered by AI
~50 spots leftby Aug 2024